Wave expects to initiate a Phase 2a multidose portion of WVE-007 INLIGHT clinical trial in individuals living with obesity ...
Wave expects to initiate a Phase 2a multidose portion of WVE-007 INLIGHT clinical trial in individuals living with obesity with higher BMI and ...
Ascidian Therapeutics ("Ascidian"), a biotechnology company seeking to treat human diseases by rewriting RNA, and Forge ...
Initial AX-0810 data show no safety signals after 4 weeks of dosing and pharmacokinetics consistent with non-clinical data; ...
New research provides a mechanistic map of how genetic mutations disrupt RNA splicing in acute myeloid leukemia.
Treating acute myeloid leukemia (AML) depends on knowing what goes wrong inside cells. A new study suggests that two genetic ...
This study provides a comprehensive evaluation of the off-target effects of ADARdd and provides guidelines for improving RNA editing accuracy in plants. The authors also emphasize that ...
The technology, called the Viral-Engineered RNA-based Activation System (VERAS), hijacks the virus's own replication ...
AZoLifeSciences on MSN
Synthetic RNA platform converts viral replication into detectable cellular signals
The technology, called the Viral-Engineered RNA-based Activation System (VERAS), hijacks the virus's own replication ...
The acquisition is centered on Dark Blue Therapeutics' small-molecule degrader of the MLLT1 and MLLT3 proteins, which is ...
AZoLifeSciences on MSN
Dual genetic mutations drive RNA mis-splicing and leukemia progression
Treating acute myeloid leukemia (AML) depends on knowing what goes wrong inside cells. A new study suggests that two genetic ...
The deal hands Amgen a drug that destroys two proteins known to drive certain types of acute myeloid leukemia, a profile that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback